Key Takeaways:
Halper Sadeh LLC is investigating Apogee Therapeutics' $10.9 billion sale to AbbVie for $135.11 a share, alleging potential breaches of fiduciary duty by the company's board.
"The investigation concerns whether Apogee and its board of directors violated federal securities laws and failed to obtain the best possible price for shareholders," the investor rights law firm said in a statement Monday.
The all-cash deal, announced June 18, values the Nasdaq-listed biotech at about $10.9 billion. Major holders including Fairmount Healthcare Fund II and affiliates of Venrock, who together control more than 15 million shares of common and non-voting stock, have entered into voting agreements committing to support the transaction, according to a regulatory filing.
The probe centers on three areas: whether the board secured adequate consideration, conducted a sales process free of conflicts, and disclosed all material information needed for shareholders to evaluate the deal. Halper Sadeh said it may seek increased consideration, additional disclosures or other relief on behalf of Apogee shareholders.
Apogee, a clinical-stage biotech focused on inflammatory and respiratory diseases, had about 38 million shares outstanding before the deal. The $135.11 offer price represents a premium to the stock's trading levels before deal speculation emerged.
The investigation adds a layer of legal risk to a transaction already requiring antitrust clearance and shareholder approval. Apogee shareholders should watch for any supplemental disclosures or competing bids ahead of the vote on the merger.
This article is for informational purposes only and does not constitute investment advice.
